原发中枢神经系统淋巴瘤的免疫化疗或单纯化疗:美国国家癌症数据库分析
该研究基于美国国家癌症数据库2013至2018年诊断的4691例原发中枢神经系统淋巴瘤患者,分析免疫治疗使用趋势及相关因素,并用倾向性评分1:1匹配2830例比较总生存。免疫治疗使用从2013年45%升至2018年76%,与总生存改善相关(HR 0.75,95%CI 0.67-0.83),年龄≤75岁患者获益更明显(HR 0.71,95%CI 0.63-0.80),>75岁患者未达统计学显著(HR 0.87,95%CI 0.70-1.08)。
要点
- 免疫治疗使用从2013年45%升至2018年76%。
- 匹配后免疫治疗与显著更好的总生存相关(HR 0.75,95%CI 0.67-0.83)。
- 年龄≤75岁患者免疫治疗获益更明显(HR 0.71,95%CI 0.63-0.80)。
核心结论
- 总体而言,研究结果支持当前使用利妥昔单抗的趋势,但治疗老年患者时应采取细致的个体化策略。
研究设计与样本
- 基于美国国家癌症数据库的回顾性分析,纳入2013至2018年诊断的4691例原发中枢神经系统淋巴瘤患者。
- 采用多变量回归模型(含随机截距以考虑医院特异性治疗选择过程)分析免疫治疗使用的相关因素。
- 采用1:1倾向性评分匹配2830例患者以限制可能的混杂因素,并在匹配队列中比较总生存。
主要发现
- 免疫治疗使用从2013年45%增至2018年76%。
- 免疫治疗使用与社会人口学变量及局部(医院层面)偏好相关,而非临床因素。
- 与免疫治疗使用减少相关的主要因素包括男性、黑种人或西班牙裔(相比白种非西班牙裔)、HIV阳性、较低容量医院治疗及较早诊断年份。
- 匹配后,接受免疫治疗与显著更好的总生存相关(HR 0.75,95%CI 0.67-0.83)。
- 按年龄存在异质性:免疫治疗优势在≤75岁患者(HR 0.71,95%CI 0.63-0.80)比>75岁患者(HR 0.87,95%CI 0.70-1.08)更明显。
临床怎么用
- 研究结果支持当前使用利妥昔单抗的趋势,但作者认为治疗老年患者时应采取细致的个体化策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Debate remains over the role of rituximab, a large molecule with reduced central nervous system (CNS) penetration, in therapy for primary CNS lymphoma (PCNSL). Since 2013, the National Cancer Database has distinguished between chemotherapy and immunotherapy for frontline treatment. In this setting, rituximab would be the only standard frontline immunotherapy. We examined factors associated with the receipt of immunotherapy using a multivariate regression model for relative risk, with a random intercept to account for the hospital-specific treatment selection process. Patients were matched using a 1:1 propensity score to limit possible confounders, and overall survival (OS) was compared in the matched cohort. We identified 4691 patients with PCNSL diagnosed between 2013 and 2018. The use of immunotherapy has increased from 45% in 2013 to 76% in 2018. Immunotherapy use was associated with sociodemographic variables and local (hospital level) preference rather than clinical factors. The main factors associated with reduced use of immunotherapy included male sex, Black race or Hispanic ethnicity (compared with White non-Hispanic), HIV+ status, treatment in a lower-volume hospital, and earlier year of diagnosis. We matched 2830 patients for the survival analysis. Receipt of immunotherapy was associated with a significantly better OS (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.67-0.83). There was heterogeneity according to age, because the advantage of immunotherapy was more pronounced for patients aged ≤75 years (HR, 0.71; 95% CI, 0.63-0.80) than for those older than 75 years (HR, 0.87; 95% CI, 0.70-1.08). Overall, our findings support the current trend toward rituximab use, although a nuanced approach should be adopted when treating older patients.
引用
- Ollila TA, Taher R, Moku P, et al. Immunochemotherapy or chemotherapy alone in primary central nervous system lymphoma: a National Cancer Database analysis. Blood Adv. 2023. PMID: 37459209. doi:10.1182/bloodadvances.2023010352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。